Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | PYGB | P11216 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14191378 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14191382 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14025371 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14278435 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL10176794 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL12221718 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL23640046 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL20340506 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL21339944 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL12242433 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780872-B2 | Oligosaccharide analytical standards | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230242499-A1 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | SYSMEX CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-24 | — | — | US | disclosed |
| US-20160153989-A1 | SELECTION OF BIOLOGICAL OBJECTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-06-02 | — | — | US | disclosed |
| US-20130012466-A1 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012466-A1 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8232254-B2 | Colchicine glycosylated to include a sugar moiety on a methoxyamino-appended colchicine; cytolysis equivalent to paclitaxel and doxorubicin; stabilizers of tubulin formation; anticarcinogenic -arthritic agents; Mediterranean fever, amyloidosis, scleroderma, irritable bowel syndrome or gout | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-8198419-B2 | Glycorandomization and production of novel erythromycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | THORSON JON | 2011-05-26 | — | — | US | disclosed |
| US-20080171787-A1 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-07-17 | — | — | US | disclosed |
| US-7348309-B2 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171787-A1 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE | TUBB6, TUBB, TUBA1C | LGALS1 138/4885LGALS3 116/4885LGALS9 464/4885 |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | LGALS1 1838/4885LGALS3 1512/4885LGALS9 1928/4885 |
| US-11780872-B2 | Oligosaccharide analytical standards | OSTC, FUT5, FUT6 | LGALS1 427/4885LGALS3 312/4885LGALS9 260/4885 |
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | FECH, SLC19A1, SLC40A1 | LGALS1 3977/4885LGALS3 4453/4885LGALS9 3026/4885 |
| US-20130012466-A1 | COLCHICINE NEOGLYCOSIDES AND METHODS FOR THEIR SYNTHESIS AND USE | TUBB6, TUBB, TUBA1C | LGALS1 138/4885LGALS3 116/4885LGALS9 464/4885 |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | NMT2, NMT1, NAMPT | LGALS1 1415/4885LGALS3 1455/4885LGALS9 1916/4885 |
| US-20230242499-A1 | COMPOUND OR SALT THEREOF, COMPOSITION, CHEMILUMINESCENCE METHOD, METHOD FOR MEASURING CHEMILUMINESCENCE SIGNAL, REAGENT, REAGENT KIT, AND METHOD FOR ASSAYING ANALYTE | JAK2, MPO, PEAK1 | LGALS1 1779/4885LGALS3 1977/4885LGALS9 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.